MGA
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| MGA, MAX dimerization protein | MIM:616061 | Ensembl:ENSG00000174197 | HGNC:HGNC:14010 | PA134976336 | 15q15.1 |
GO terms in MGA
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0071339 | MLL1 complex |
| BP | IEA | GO:0006351 | transcription, DNA-templated |
| BP | IEA | GO:0006357 | regulation of transcription by RNA polymerase II |
| BP | TAS | GO:0070317 | negative regulation of G0 to G1 transition |
| MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | IEA | GO:0003677 | DNA binding |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0046983 | protein dimerization activity |
Gene expression in normal tissue: MGA
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MGA
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-212436 | Generic Transcription Pathway |
| reactome | R-HSA-73857 | RNA Polymerase II Transcription |
| reactome | R-HSA-74160 | Gene expression (Transcription) |
| reactome | R-HSA-8953750 | Transcriptional Regulation by E2F6 |
| wikipathways | WP3651 | Pathways Affected in Adenoid Cystic Carcinoma |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD260 | FQI-2 | 5 |
| iGMDRD226 | ML006 | 3 |
| iGMDRD188 | Piperlongumine | 1 |
| iGMDRD74 | Idarubicin | 8 |
| iGMDRD888 | Compound 44 | 3 |
| iGMDRD506 | Fedratinib | 3 |
| iGMDRD780 | PP-30 | 2 |
| iGMDRD64 | Parbendazole | 5 |
| iGMDRD23 | Gossypol | 2 |
| iGMDRD356 | PNU-74654 | 1 |
| iGMDRD151 | CHM-1 | 2 |
| iGMDRD427 | ABT737 | 4 |
| iGMDRD779 | PRL-3 Inhibitor I | 4 |
| iGMDRD639 | YK 4-279 | 1 |
| iGMDRD61 | Kinetin riboside | 3 |
| iGMDRD672 | Alectinib | 1 |
| iGMDRD158 | NSC141540 | 3 |
| iGMDRD121 | GMX1778 | 1 |
| iGMDRD137 | Indisulam | 9 |
| iGMDRD105 | Triptolide | 2 |
| iGMDRD215 | CCT007093 | 1 |
| iGMDRD372 | TGX 221 | 1 |
| iGMDRD286 | Nsc 632839 | 2 |
| iGMDRD367 | Ro 28-1675 | 3 |
| iGMDRD200 | STF62247 | 1 |
| iGMDRD329 | Merck60 | 3 |
| iGMDRD366 | PI-103 | 2 |
| iGMDRD552 | AZD-1775 | 3 |
| iGMDRD322 | FK 866 | 1 |
| iGMDRD532 | Olaparib | 1 |
| iGMDRD79 | Gemcitabine | 3 |
| iGMDRD775 | NCGC00346967-01 | 1 |
| iGMDRD314 | Tanespimycin | 2 |
| iGMDRD123 | Isoevodiamine | 4 |
| iGMDRD1002 | rTRAIL | 1 |
| iGMDRD605 | AZD6482 | 1 |
| iGMDRD154 | NSC23766 | 3 |
| iGMDRD883 | CIL55A | 1 |
| iGMDRD270 | Ciclosporin | 2 |
| iGMDRD480 | KU0060648 | 2 |
| iGMDRD255 | SB225002 | 1 |
| iGMDRD782 | DC-45-A2 | 1 |
| iGMDRD441 | TW 37 | 1 |
| iGMDRD100 | Zebularine | 2 |
| iGMDRD887 | Compound 23 citrate | 2 |
| iGMDRD577 | BIX01294 | 3 |
| iGMDRD398 | Sepantronium | 4 |
| iGMDRD562 | Navitoclax | 2 |
| iGMDRD371 | THR1 Inhibitor | 1 |
| iGMDRD772 | BRD4770 | 2 |
| iGMDRD446 | LY 2183240 | 1 |
| iGMDRD193 | Fqi1 | 5 |
| iGMDRD280 | CYTOCHALASIN B | 4 |
| iGMDRD481 | Dactolisib | 2 |
| iGMDRD886 | Compound 1541A | 2 |
| iGMDRD246 | NPC26 | 5 |
| iGMDRD82 | Quiflapon | 2 |
| iGMDRD84 | Lovastatin acid | 6 |
| iGMDRD345 | Compound 10b [PMID: 11504634] | 1 |
| iGMDRD652 | UNC0638 | 2 |
| iGMDRD85 | Ursolic acid | 6 |
| iGMDRD57 | Chloropentafluorobenzene | 2 |
| iGMDRD901 | ELCPK | 1 |
| iGMDRD450 | JNJ-26854165 | 1 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MGA
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.